BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
News|Articles|August 20, 2026
When Is a Carcinogen Really a Carcinogen?
Fact checked by: Forrest N. Ridgway, PharmD, BCOP, Tracy Ann Politowicz
Decode carcinogens: IARC hazard vs risk, what "possibly" means, and how pharmacists ease aspartame, meat, and phone fears.
Advertisement
Advertisement
Few headlines generate more patient anxiety than “[insert name of item] classified as possible carcinogen.” In recent years, aspartame, red meat, cell phones, and aloe vera have all received some form of carcinogen designation—triggering patient questions, social media panic, and genuine confusion in the oncology clinic.
Related to this article
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Advertisement
Advertisement